Current Price
Target Price
Analyst Sentiment
4 ratings: Buy
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. The company is headquartered in Paramus, New Jersey.
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2025 | FY 2026 | FY 2026 | FY 2026 | FY 2026 | FY 2027 | FY 2027 |
|---|---|---|---|---|---|---|---|
| $-0.02 | $-0.02 | $-0.04 | $-0.04 | $-0.18 | $-0.07 | $-0.28 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| — | +33.3% | +20.0% | +10.5% | +5.1% | +4.5% | +3.5% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | IIkena Onco... | IMA | $43.22M | — | 0.34 | — | — | -82.70% | — |
| 2. | KKalaris Th... | KLRS | $37.49M | — | 0.79 | — | — | -97.20% | — |
| 3. | MMural Onco... | MURA | $35.38M | — | 0.64 | — | — | -103.90% | — |
| 4. | BBoundless... | BOLD | $59.03M | — | 0.96 | — | — | -64.60% | — |
| 5. | AAardvark T... | AARD | $29.12M | — | 0.39 | — | — | -66.00% | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - | - | - | - | - |
| 0.77 | 0.72 | 5.05 | 0.88 | 0.97 | 0.91 | 1.96 | 1.38 | |
EBIT | -0.77 | -0.72 | -5.05 | -0.88 | -0.97 | -0.91 | -1.96 | -1.38 |
OPM % | - | - | - | - | - | - | - | - |
Non-Operating Income | 0 | 0 | 0 | -0.12 | -0.46 | -0.58 | -0.59 | 0 |
PBT | -0.77 | -0.72 | -5.05 | -1.01 | -1.43 | -1.5 | -2.54 | -1.38 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | -0.77 | -0.72 | -5.05 | -1.01 | -1.43 | -1.5 | -2.54 | -1.38 |
NPM % | - | - | - | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
Revenue | 0 | 0 | 0 |
COGS | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 |
Gross Profit % | - | - | - |
| 3.78 | 4.35 | 7.82 | |
EBIT | -3.78 | -4.35 | -7.82 |
OPM % | - | - | - |
Non-Operating Income | 0 | -26 | -1.16 |
PBT | -3.78 | -30.36 | -8.98 |
Income Tax | 0 | 0 | 0 |
Tax Rate % | - | - | - |
Net Income | -3.78 | -30.36 | -8.98 |
NPM % | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| 0 | 4.62 | 5.14 | |
| 0 | 0 | 0 | |
| 0 | 0 | 0 | |
| 2.31 | 0.38 | 0.03 | |
| 0 | 0 | 0.25 | |
Total Assets | 2.31 | 5 | 5.42 |
| 0 | 0.02 | 0.01 | |
| 1.27 | 4.7 | 4.56 | |
| 0.13 | 0 | 0 | |
| 0.91 | 0.29 | 0.6 | |
| 0 | 0 | 0.25 | |
Total Liabilities | 2.31 | 5 | 5.42 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| -0.17 | -2.57 | -3.94 | |
| 0 | 0 | 0 | |
| 0.13 | 7.19 | 4.47 | |
Net CFNet Cash Flow | -0.04 | 4.62 | 0.52 |
FCFFree Cash Flow | -0.17 | -2.57 | -3.94 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| - | -1013.7% | -193.7% | |
| 0.10 | - | - | |
| 2.23 | 17.30 | 8.55 | |
| - | 0.00 | 0.00 | |
Cash Conversion | 0.05 | 0.08 | 0.44 |
Payout Ratio | - | - | - |
| - | - | - | |
| - | - | - | |
| - | - | - | |
| 3.00 | 3.00 | 4.00 | |
| - | - | - | |
| 50.00 | 0.00 | 0.00 | |
| - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Polaryx Therapeutics Inc, from SEC filings
No SEC ownership filings for this company yet.
Polaryx Therapeutics Inc's SEC filings and earnings call transcripts
No SEC filings for this company yet.
What recent news says about Polaryx Therapeutics Inc, scored for sentiment.